| Followers | 141 |
| Posts | 5785 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Thursday, January 01, 2026 10:49:06 AM
From this Nature article:
https://www.nature.com/articles/s41467-024-48073-y
DCVax-L is the commercially branded version of UCLAs ATL-DC. There is one and only one ATL-DC used by UCLA. And NWBO has the commercial rights.
You keep forgetting that there is an article out there where in print Dr. Liau says that NWBO took her formula and tweaked it to call it their own.
- learningcurve2020
That’s quite bold LC considering the dozens of proof that states the opposite, that has been put forward by UCLA in terms of Nature results article, UCLA articles, verbally stated by UCLA doctors, stated by Linda Liau in webinar with Al Musella in 2022, in slides at several Linda Liau seminars.
How come you keep forgetting that?
Can you enlighten us about your incentive to stay voluntarily in the dark for years on this topic in particular?
The outcome may be the same but the process was tweaked so NWBO could call it their own. Why is this so hard? Tell you what, write LP to please put a clear explanation up on their website so we can all finally call it a day on this topic.
- learningcurve2020
It is clear but only to those, who are invested in NWBO. Not the uninvested segment.
How might that be?
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM

